Evaluation Of Elf-Napsin A As A Diagnostic Biomarker For Primary Lung Adenocarcinoma Using Bronchoscopic Microsampling
Main Article Content
Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with primary lung adenocarcinoma being the most frequently diagnosed subtype. While serum biomarkers such as carcinoembryonic antigen (CEA) and sialyl Lewis Xi antigen (SLX) are commonly used in clinical practice, their sensitivity and specificity for early-stage diagnosis remain inadequate. This study evaluates the diagnostic potential of napsin A levels in epithelial lining fluid (ELF) obtained through bronchoscopic microsampling (BMS) as a biomarker for primary lung adenocarcinoma.
Methods: A total of 70 patients with peripheral lung nodules underwent BMS, followed by surgical resection for definitive diagnosis. ELF samples were collected from both the nodule site and contralateral lung, and napsin A and CEA levels were measured. Receiver operating characteristic (ROC) curve analysis was conducted to compare the diagnostic performance of ELF-napsin A and ELF-CEA.
Results:
ELF-napsin A levels were significantly elevated at nodule sites in patients with primary lung adenocarcinoma compared to contralateral sites and non-adenocarcinoma cases. ROC analysis demonstrated a superior area under the curve (AUC) for ELF-napsin A (0.876) compared to ELF-CEA (0.560).Conclusion: ELF-napsin A is a promising biomarker for detecting primary lung adenocarcinoma with higher diagnostic accuracy than ELF-CEA. The non-invasive BMS technique allows for efficient ELF collection, making it a viable alternative to traditional biopsy methods. Further studies with larger cohorts are needed to validate these findings and assess its potential in early-stage lung cancer diagnosis.
Article Details
References
World Health Organization. Cancer. Fact Sheet Number 297. www.who. int/mediacentre/factsheets/fs297/en/ Last updated February 2015. Accessed 10 Feb 2015.
Kennedy GT, Okusanya OT, Keating JJ, Heitjan DF, Deshpande C, Litzky LA, Albelda SM, Drebin JA, Nie S, Low PS, et al. The optical biopsy: a novel technique for rapid Intraoperative diagnosis of primary pulmonary Adenocarcinomas. Ann Surg. 2015;262(4):602–9.
Lim HJ, Ahn S, Lee KS, Han J, Shim YM, Woo S, Kim JH, Yie M, Lee HY, Yi CA. Persistent pure ground-glass opacity lung nodules >/= 10 mm in diameter at CT scan: histopathologic comparisons and prognostic implications. Chest. 2013;144(4):1291–9.
Slatore CG, Horeweg N, Jett JR, Midthun DE, Powell CA, Wiener RS, Wisnivesky JP, Gould MK. An official American Thoracic Society research Table 2 ROC analysis comparing ELF-napsin A and ELF-CEA AUC 95% CI, % Cut off point Sensitivity, % Specificity, % PPV, % NPV, % Positive LR Negative LR ELF-napsin A 0.840 72.8 to 95.3 3280 ng∙mL−1 79.3 82.9 76.7 85.0 4.64 0.25 ELF-CEA 0.542 40.7 to 67.8 82 ng∙mL−1 75.9 34.1 44.9 66.7 1.15 0.71 ELF Epithelial lining fluid, CEA Carcinoembryonic antigen, AUC Area under the ROC curve, CI Confidence interval, PPV Positive predictive value, NPV Negative predictive value, LR Likehood ratio Uchida et al. BMC Pulmonary Medicine (2017) 17:195 Page 8 of 9 statement: a research framework for pulmonary nodule evaluation and management. Am J Respir Crit Care Med. 2015;192(4):500–14.
Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, Tsubota N. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg. 2004;78(1):216–21.
Zenita K, Kirihata Y, Kitahara A, Shigeta K, Higuchi K, Hirashima K, Murachi T, Miyake M, Takeda T, Kannagi R. Fucosylated type-2 chain polylactosamine antigens in human lung cancer. Int J Cancer. 1988;41(3):344–9.
Satoh H, Ishikawa H, Kamma H, Yamashita YT, Takahashi H, Ohtsuka M, Hasegawa S. Serum sialyl lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival. Clin Cancer Res. 1997;3(4):495–9.
Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e142S–65S.
Wiener RS, Wiener DC, Gould MK. Risks of transthoracic needle biopsy: how high? Clin Pulm Med. 2013;20(1):29–35.
Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med. 2011;155(3):137–44.